aTyr Pharma
ATYR
36 hedge funds and large institutions have $39.8M invested in aTyr Pharma in 2022 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 12 increasing their positions, 8 reducing their positions, and 5 closing their positions.
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
50% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 8
9% more funds holding
Funds holding: 33 → 36 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3.31% less ownership
Funds ownership: 66.57% → 63.27% (-3.3%)
30% less capital invested
Capital invested by funds: $57.2M → $39.8M (-$17.4M)
80% less call options, than puts
Call options by funds: $18K | Put options by funds: $91K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
+$1.01M |
| 2 |
Walleye Capital
New York
|
+$809K |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
+$707K |
| 4 |
TI
Telemetry Investments
New York
|
+$310K |
| 5 |
Millennium Management
New York
|
+$161K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$2.33M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$1.8M |
| 3 |
VA
VR Adviser
New York
|
-$536K |
| 4 |
BBA
Baker Bros. Advisors
New York
|
-$455K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$137K |
ATYR Hedge Fund Activity: Q4 2022 in Review
36 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in aTyr Pharma (ATYR) for Q4 2022, worth a combined $39.8M — down 30% from $57.2M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new ATYR positions and 5 closed out — a net gain of 3 holders — while 12 added to existing stakes and 8 trimmed.
The largest buyer was Citigroup, opening a new position worth an estimated $1.01M. The largest seller was Tang Capital Management, cutting an estimated $2.33M.
- 36 institutional investors held aTyr Pharma (ATYR) as of Q4 2022, up from 33 in Q3 2022.
- Funds reported $39.8M of aTyr Pharma stock for Q4 2022, down 30% quarter-over-quarter.
- 8 funds opened new aTyr Pharma positions in Q4 2022 and 5 closed out, a net change of +3 holders.
- The largest aTyr Pharma buyer in Q4 2022 was Citigroup, an estimated $1.01M added.
- The largest aTyr Pharma seller in Q4 2022 was Tang Capital Management, an estimated $2.33M sold.
Based on aggregated 13F filings for Q4 2022.